Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 2-ethylbutyl ((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate-2,3,3,3-d4
Purity: ≥99% deuterated forms (d1-d4)
Formula Markup: C27H31D4N6O8P
Formula Weight: 606.600441
CAS Number: 2738376-82-2
Notes: Remdesivir-d4 is intended for use as an internal standard for the quantification of remdesivir (Item No. 30354) by GC- or LC-MS. Remdesivir is a prodrug form of the antiviral nucleoside analog GS-441524 (Item No. 30469).{45842,45860} Upon entry into cells, remdesivir is metabolized into a nucleoside monophosphate form, which is further metabolized to an active nucleotide triphosphate that induces RNA chain termination and inhibits viral polymerases.{52859} Remdesivir reduces viral titers in primary human airway epithelial (HAE) cells infected with Middle East respiratory syndrome coronavirus (MERS-CoV) or severe acute respiratory syndrome CoV (SARS-CoV; EC50s = 0.074 and 0.069 µM, respectively). It reduces infectious virus production in SARS-CoV-2-infected HAE cells (EC50 = 10 nM).{61140} In vivo, remdesivir (25 and 50 mg/kg) reduces lung viral titers and prevents weight loss in a mouse model of SARS-CoV infection.{45860} Remdesivir (25 mg/kg) also reduces lung viral titers and lung hemorrhage and improves pulmonary function in mice infected with a chimeric SARS-CoV encoding the SARS-CoV-2 RNA-dependent RNA polymerase (RdRP).{61140} Formulations containing remdesivir have been used in the treatment of COVID-19.
English
Deutsch
